Binary lipids-based nanostructured lipid carriers for improved oral bioavailability of silymarin

Journal of Biomaterials Applications

Volumn 28, Issue 6, 2014, Pages 887-896

  Shangguan, Mingzhu ^a   Lu, Yi ^a   Qi, Jianping ^a   Han, Jin ^b   Tian, Zhiqiang ^a   Xie, Yunchang ^a   Hu, Fuqiang ^c   Yuan, Hailong ^b   Wu, Wei ^a  

^a FUDAN UNIVERSITY   (China)

^b BEIJING 302 HOSPITAL   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

glycerol distearate; Nanostructured lipid carrier; oleic acid; oral bioavailability; silymarin

Indexed keywords

BIOAVAILABILITY ENHANCEMENTS; ENTRAPMENT EFFICIENCY; HIGH PRESSURE HOMOGENIZATION; LYMPHATIC TRANSPORT; MEAN PARTICLE SIZE; NANOSTRUCTURED LIPID CARRIERS; ORAL BIOAVAILABILITIES; SILYMARIN;

BIOCHEMISTRY; DRUG DELIVERY; GLYCEROL; HOMOGENIZATION METHOD; LIPIDS; OLEIC ACID;

FLAVONOIDS;

EMULSIFYING AGENT; GLYCEROL; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; OLEIC ACID; PHOSPHATIDYLCHOLINE; POLYSORBATE 80; SILYMARIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BEAGLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG PELLET; DRUG RELEASE; DRUG SOLUBILITY; DRUG TRANSPORT; IN VITRO STUDY; LIPOLYSIS; NANOFABRICATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; ZETA POTENTIAL;

GLYCEROL DISTEARATE; NANOSTRUCTURED LIPID CARRIER; OLEIC ACID; ORAL BIOAVAILABILITY; SILYMARIN;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DOGS; LIPIDS; LIPOLYSIS; MICROSCOPY, ELECTRON, TRANSMISSION; NANOSTRUCTURES; PARTICLE SIZE; SILYMARIN;

EID: 84891590387     PISSN: 08853282     EISSN: 15308022     Source Type: Journal    
DOI: 10.1177/0885328213485141     Document Type: Article

References (40)

1. Wen Z, Dumas TE, Schrieber SJ, et al. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos. 2008 ; 36: 65-72
2. Lu C, Lu Y, Chen J, et al. Synchronized and sustained release of multiple components in silymarin from erodible glyceryl monostearate matrix system. Eur J Pharm Biopharm. 2007 ; 66: 210-219
3. Abenavoli L, Milic N and Capasso F. Anti-oxidant therapy in non-alcoholic fatty liver disease: the role of silymarin. Endocrine 2012; 42: 754-755.
4. Fried MW, Navarro VJ, Afdhal N, et al. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis c unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA. 2012 ; 308: 274-282
5. Luper S. A review of plants used in the treatment of liver disease: Part 1. Altern Med Rev. 1998 ; 3: 410-421
6. Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice. World J Gastroenterol. 2011 ; 17: 2288-2301
7. Rainone F. Milk thistle. Am Fam Physician 2005; 72: 1285-1288.
8. Pepping J. Milk thistle: Silybum marianum. Am J Health Syst Pharm 1999; 56: 1195-1197.
9. Wu W, Wang Y, Que L. Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. Eur J Pharm Biopharm. 2006 ; 63: 288-294
10. Li X, Yuan Q, Huang Y, et al. Development of silymarin self-microemulsifying drug delivery system with enhanced oral bioavailability. AAPS PharmSciTech. 2010 ; 11: 672-678
11. Woo JS, Kim TS, Park JH, et al. Formulation and biopharmaceutical evaluation of silymarin using smedds. Arch Pharm Res. 2007 ; 30: 82-89
12. Cao X, Fu M, Wang L, et al. Oral bioavailability of silymarin formulated as a novel 3-day delivery system based on porous silica nanoparticles. Acta Biomater. 2012 ; 8: 2104-2112
13. Sun N, Zhang X, Lu Y, et al. In vitro evaluation and pharmacokinetics in dogs of solid dispersion pellets containing Silybum marianum extract prepared by fluid-bed coating. Planta Med. 2008 ; 74: 126-132
14. Lian R, Lu Y, Qi J, et al. Silymarin glyceryl monooleate/poloxamer 407 liquid crystalline matrices: physical characterization and enhanced oral bioavailability. AAPS PharmSciTech. 2011 ; 12: 1234-1240
15. Yan-Yu X, Yun-Mei S, Zhi-Peng C, et al. Preparation of silymarin proliposome: a new way to increase oral bioavailability of silymarin in beagle dogs. Int J Pharm. 2006 ; 319: 162-168
16. Yanyu X, Yunmei S, Zhipeng C, et al. The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats. Int J Pharm. 2006 ; 307: 77-82
17. He J, Hou S, Lu W, et al. Preparation, pharmacokinetics and body distribution of silymarin-loaded solid lipid nanoparticles after oral administration. J Biomed Nanotech. 2007 ; 3: 195-202
18. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007 ; 6: 231-248
19. Jenning V, Thunemann AF, Gohla SH. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm. 2000 ; 199: 167-177
20. Qi J, Lu Y, Wu W. Absorption, disposition and pharmacokinetics of solid lipid nanoparticles. Curr Drug Metab. 2012 ; 13: 418-428
21. Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002 ; 54: S131 - S155
22. Muchow M, Maincent P, Muller RH. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm. 2008 ; 34: 1394-1405
23. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech. 2011 ; 12: 62-76
24. Zhuang CY, Li N, Wang M, et al. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm. 2010 ; 394: 179-185
25. Zheng D, Dai W, Zhang D, et al. In vivo studies on the oridonin-loaded nanostructured lipid carriers. Drug Deliv. 2012 ; 19: 286-291
26. Muchow M, Maincent P, Muller RH, et al. Production and characterization of testosterone undecanoate-loaded NLC for oral bioavailability enhancement. Drug Dev Ind Pharm. 2011 ; 37: 8-14
27. Muller RH, Runge SA, Ravelli V, et al. Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation. Eur J Pharm Biopharm. 2008 ; 68: 535-544
28. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000 ; 50: 161-177
29. Mehnert W and Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001; 47: 165 - 196.
30. Sun N, Wei X, Wu B, et al. Enhanced dissolution of silymarin/ polyvinylpyrrolidone solid dispersion pellets prepared by a one-step fluid-bed coating technique. Powder Technol. 2008 ; 182: 72-80
31. Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery. Ii. Drug incorporation and physicochemical characterization. J Microencapsul. 1999 ; 16: 205-213
32. Porter CJ, Charman WN. In vitro assessment of oral lipid based formulations. Adv Drug Deliv Rev. 2001 ; 50: S127 - S147
33. Porter CJ, Kaukonen AM, Boyd BJ, et al. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharm Res. 2004 ; 21: 1405-1412
34. Jia L, Zhang D, Li Z, et al. Nanostructured lipid carriers for parenteral delivery of silybin: biodistribution and pharmacokinetic studies. Colloids Surf B Biointerf. 2010 ; 80: 213-218
35. Muller RH, Petersen RD, Hommoss A, et al. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev. 2007 ; 59: 522-530
36. Larsen AT, Sassene P, Mullertz A. In vitro lipolysis models as a tool for the characterization of oral lipid and surfactant based drug delivery systems. Int J Pharm. 2011 ; 417: 245-255
37. MacGregor KJ, Embleton JK, Lacy JE, et al. Influence of lipolysis on drug absorption from the gastro-intestinal tract. Adv Drug Deliver Rev. 1997 ; 25: 33-46
38. Dahan A, Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Release. 2008 ; 129: 1-10
39. Cuine JF, McEvoy CL, Charman WN, et al. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs. J Pharm Sci. 2008 ; 97: 995-1012
40. Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev. 2008 ; 60: 702-716